Meeting
2019 Genitourinary Cancers Symposium
Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?
Authors
Marc Dall'era
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Marc Dall'era , Christopher P. Evans , Chong-Xian Pan , Mamta Parikh , Primo Lara Jr., John McPherson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 19)
DOI
10.1200/JCO.2019.37.7_suppl.19
Abstract #
19
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients.
First Author: Leylah M. Drusbosky
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.
First Author: Philippe E. Spiess
Poster
2018 ASCO Annual Meeting
Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joaquin Mateo
Poster
2018 ASCO Annual Meeting
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.
First Author: Rahul Raj Aggarwal